MedPath

R1vascular Hepatectomy for HCC Patients

Completed
Conditions
Hepatocellular Carcinoma
Registration Number
NCT03476421
Lead Sponsor
Humanitas Clinical and Research Center
Brief Summary

Since the previous decade, the authors introduced the R1 vascular (R1vasc) resection for the treatment of hepatocellular carcinoma (HCC), and colorectal liver metastases (Torzilli et al. J Am Coll Surg 2005; Viganò et al. Ann Surg Oncol 2016; Torzilli et al. Surgery 2017). However, oncological reliability of tumor exposure in surgery for HCC remains controversial since it has never been validated. The aim of the study is to determine the oncological adequacy of R1vasc hepatectomy in patients with HCC.

Detailed Description

A prospective cohort of patients who underwent hepatectomy for HCC between January 2005 and December 2015 is reviewed. The following definitions are adopted: R0 is any resection with at least 1 mm of negative margin; R1vasc is any resection with tumor exposure due to the detachment from major intrahepatic vessel (1st/2nd order glissonean pedicles and hepatic vein at caval confluence); R1-parenchymal (R1par) is any resection with tumor exposure at parenchymal margin.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
327
Inclusion Criteria
  • only patients with a primary untreated HCC were included;
  • complete follow-up data with available computed tomography (CT) and/or magnetic resonance imaging (MRI) images showing the first recurrence
Exclusion Criteria
  • patients who underwent vascular resection for direct infiltration of the vessel wall
  • patients who had radiofrequency ablation in association to surgery

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Rates of local recurrenceFrom date of surgery until the date of first documented progression or date of death from any cause, which ever came first assessed up to 72 months

Calculation of the local recurrence (cut-edge tumor re-growth) of R0, R1par, and R1vasc, and R1par+R1vasc hepatectomy.

Secondary Outcome Measures
NameTimeMethod

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.